Northwestern Mutual Wealth Management Co. Has $3.79 Million Stock Position in Alto Neuroscience, Inc. $ANRO

Northwestern Mutual Wealth Management Co. lifted its position in Alto Neuroscience, Inc. (NYSE:ANRO) by 14,567.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 212,672 shares of the company’s stock after buying an additional 211,222 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Alto Neuroscience were worth $3,786,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Geode Capital Management LLC lifted its stake in shares of Alto Neuroscience by 20.8% in the fourth quarter. Geode Capital Management LLC now owns 287,435 shares of the company’s stock worth $5,118,000 after buying an additional 49,535 shares during the last quarter. AlphaCore Capital LLC lifted its stake in shares of Alto Neuroscience by 100.0% in the fourth quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $356,000 after buying an additional 10,000 shares during the last quarter. Torren Management LLC acquired a new stake in shares of Alto Neuroscience in the fourth quarter worth $62,000. Armistice Capital LLC lifted its stake in shares of Alto Neuroscience by 0.7% in the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after buying an additional 12,000 shares during the last quarter. Finally, Susquehanna International Group LLP lifted its stake in shares of Alto Neuroscience by 154.9% in the third quarter. Susquehanna International Group LLP now owns 155,676 shares of the company’s stock worth $626,000 after buying an additional 94,613 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ANRO. Weiss Ratings upgraded shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. BTIG Research upped their target price on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Robert W. Baird cut their target price on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Chardan Capital reiterated a “buy” rating and set a $30.00 target price on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Finally, Wolfe Research began coverage on shares of Alto Neuroscience in a research note on Friday, May 22nd. They set an “outperform” rating for the company. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Price Performance

NYSE:ANRO opened at $20.05 on Friday. The stock has a market cap of $703.60 million, a P/E ratio of -8.28 and a beta of 1.22. Alto Neuroscience, Inc. has a one year low of $2.15 and a one year high of $28.44. The company has a fifty day moving average price of $22.86 and a 200 day moving average price of $19.30. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). Analysts anticipate that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current year.

Alto Neuroscience Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.